THE US Food and Drug Administration has granted regular approval to Tagrisso (osimertinib from AstraZeneca) for the treatment of patients with a specific mutation-positive form of non-small cell lung cancer.
The drug had previously been granted accelerated approval for this indication and was approved in the UK in Oct 2016 (PD 06 16).
Tagrisso has been registered in Australia since 03 Aug 2016.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Apr 17
